In a recent unveiling at the 2024 Conference on Retroviruses and Opportunistic I...
NovAliX, a specialized contract research company that is committed to facilitati...
Bispecific T-cell engagers are gaining prominence in oncology, yet this hasn’t d...
Agiliti is withdrawing from the public market, a move that comes less than three...
In recent developments, the FDA has greenlighted one antibiotic combination ther...
AstraZeneca and FibroGen have concluded their collaboration on the oral anemia m...
The Laboratorios Farmacéuticos Rovi and Moderna partnership has recently achieve...
Recent mouse study findings suggest that epigenetic gene silencing could effecti...
Xolair, a medication jointly marketed by Roche and Novartis, has emerged as a so...
In a recent investigation, scientists scrutinized the genetic composition of 250...
Bristol Myers Squibb (BMS) has disclosed a significant infusion of $400 million ...
Amidst the concerning rise of drug-resistant strains of gonorrhea, a recent brea...
Rapt Therapeutics faces a daunting challenge as the U.S. Food and Drug Administr...
The European Commission has granted its approval to Pfizer’s Velsipity for the t...
The Food and Drug Administration (FDA) has granted approval to AstraZeneca’s Tag...
The emergence of T-cell therapy has revolutionized the treatment of certain bloo...
